SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?


To: Dr. John M. de Castro who wrote (773)12/5/1999 11:52:00 AM
From: Mike McFarland  Read Replies (1) | Respond to of 4474
 
< This suggests that Ariad will incur $6MM in increased
expenses over the next year to fund this program.>

If shareholder's wanted to draft a joint letter to
ask this list of questions, I nominate you to do
the job. I do not see the point of 6M in extra
expenses...the number could be anything, the whole
nature of that program changes. Here are the scraps
we have been given:

upon closing of the sale ARIAD will receive
$40 million in cash; return of approximately three
million shares of ARIAD series B convertible preferred stock;
forgiveness of approximately $2 million long-term debt held
by Hoechst Marion Roussel; and rights to compounds and
related technologies resulting from a collaboration on the
development of Src tyrosine kinase inhibitors.
Hoechst Marion Roussel will receive certain payments
related to approval and commercial sale of Src inhibitors.


and
This transaction with Hoechst Marion Roussel is the first step in
redefining our business. This restructuring of our relationship
with HMR will allow ARIAD to focus on near-term development
programs and its own products with the goal of bringing one
of our proprietary osteoporosis drug candidates to the
clinic as soon as possible," said Harvey J. Berger, M.D.,
chairman and CEO of ARIAD.


I could not get any hits on AP22408, so maybe it's another.
That is as far as my homework ever went...maybe you have
dug deeper--into other documents--do you have access to
everything at rcap?